Can a targeted drug slow deadly brain cancer?

NCT ID NCT01339052

Completed Disease control Sponsor: L. Nicolas Gonzalez Castro, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase II trial tests whether the experimental drug BKM120 can slow or stop the growth of recurrent glioblastoma, an aggressive brain cancer, in patients whose tumors have an activated PI3K pathway. Some participants take the drug before surgery to see if it reaches the brain effectively, while others receive it alone to measure progression-free survival. The goal is to determine if BKM120 offers a new way to control this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called BKM120 (buparlisib)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a type of brain cancer with few effective therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. It is also limited to patients with a specific genetic marker.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
UT, MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.